D. E. Shaw & Co. Inc. raised its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 31.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,598,642 shares of the biotechnology company’s stock after buying an additional 628,870 shares during the quarter. D. E. Shaw & Co. Inc. owned about 2.64% of Momenta Pharmaceuticals worth $28,689,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 14.0% during the fourth quarter. BlackRock Inc. now owns 13,775,141 shares of the biotechnology company’s stock worth $152,079,000 after buying an additional 1,694,797 shares in the last quarter. FMR LLC grew its holdings in shares of Momenta Pharmaceuticals by 1.0% in the third quarter. FMR LLC now owns 11,747,215 shares of the biotechnology company’s stock valued at $308,951,000 after purchasing an additional 113,380 shares during the period. Vanguard Group Inc grew its holdings in shares of Momenta Pharmaceuticals by 3.8% in the third quarter. Vanguard Group Inc now owns 7,597,950 shares of the biotechnology company’s stock valued at $199,827,000 after purchasing an additional 280,177 shares during the period. Vanguard Group Inc. grew its holdings in shares of Momenta Pharmaceuticals by 3.8% in the third quarter. Vanguard Group Inc. now owns 7,597,950 shares of the biotechnology company’s stock valued at $199,827,000 after purchasing an additional 280,177 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Momenta Pharmaceuticals by 10.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,118,942 shares of the biotechnology company’s stock valued at $12,353,000 after purchasing an additional 103,474 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

In other Momenta Pharmaceuticals news, insider Jo Ann Beltramello sold 29,167 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $14.20, for a total value of $414,171.40. Following the transaction, the insider now owns 112,166 shares of the company’s stock, valued at $1,592,757.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce Downey sold 13,000 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $14.51, for a total transaction of $188,630.00. Following the completion of the transaction, the director now directly owns 41,234 shares in the company, valued at approximately $598,305.34. The disclosure for this sale can be found here. Insiders sold 84,111 shares of company stock worth $1,158,489 in the last ninety days. 3.70% of the stock is currently owned by corporate insiders.

Shares of MNTA opened at $13.77 on Thursday. Momenta Pharmaceuticals, Inc. has a 12-month low of $9.55 and a 12-month high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.39. Momenta Pharmaceuticals had a negative net margin of 232.92% and a negative return on equity of 47.74%. The company had revenue of $42.80 million for the quarter, compared to analysts’ expectations of $17.11 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 33.7% compared to the same quarter last year. As a group, research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

A number of brokerages recently issued reports on MNTA. BTIG Research began coverage on shares of Momenta Pharmaceuticals in a report on Monday. They issued a “neutral” rating and a $14.15 price objective for the company. BidaskClub lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Stifel Nicolaus reissued a “buy” rating and issued a $29.00 price objective on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $16.00 price objective on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and an average target price of $22.03.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2019/03/21/d-e-shaw-co-inc-grows-stake-in-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

See Also: Outstanding Shares

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.